Table 5 Standardized direct and indirect effects on the likelihood of an FOBT uptake

Susceptibility

.02 (−.08, .10)

−.02 (−.08, .03)

.00 (−.11, .10)

.01 (−.10, .13)

.00 (−.07, .06)

.01 (−.11, .14)

.01 (−.12, .15)

−.03 (−.13, .06)

−.02 (−.18, .14)

Severity

.08 (−.02, .20)

.08^* (.01, .18)

.16^* (.01, .33)

.14 (−.04, .34)

.08^* (.01, .20)

.22^* (.02, .46)

.03 (−.11, .17)

.05 (−.05, .20)

.08 (−.11, .27)

Benefits

.21^** (.10, .36)

.09^** (.03, .18)

.30^** (.16, .48)

.21^** (.06, .41)

.10^** (.03, .24)

.31^** (.11, .54)

.17^* (.03, .37)

.12^* (.01, .24)

.29^** (.13, .51)

Barriers

−.03 (−.15, .08)

−.16^** (−.27, −.09)

−.19^** (−.33, −.08)

−.13^* (−.29, −.01)

−.12^** (−.27, −.04)

−.25^** (−.46, −.11)

.07 (−.10, .27)

−.22^** (−.40, −.11)

−.15 (−.34, .03)

Cues to action

−.04 (−.17, .09)

–

−.04 (−.17, .09)

−.06 (−.29, .11)

–

−.06 (−.29, .11)

−.01 (−.19, .16)

–

−.01 (−.19, .16)

Self-efficacy

.53^** (.35, .69)

–

.53^** (.35, .69)

.44^** (.24, .69)

–

.44^** (.24, .69)

.66^** (.41, .83)

–

.66^** (.41, .83)